Abdominal Computed Tomography Findings of Malignant Tumors in Patients With Solid Organ Transplants

Ulu, Esra Meltem Kayahan; Tutar, Nihal Uslu; Çoşkun, Mehmet; Töre, Hüseyin Gürkan; Guvenc, Zeynep; Haberal, Mehmet

doi:10.1016/j.transproceed.2007.02.025

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following liver transplantation, PTLD may develop in the liver, but overall this is a rare complication (Barkholt et al 1991;Mulvihill et al 1994;Pickhardt and Siegel 1999;Nuckols et al 2000;Wu et al 2001;Jain et al 2002;Gouya et al 2006;Avolio et al 2007;Ulu et al 2007). Hepatic PTLD in a grafted liver may be of donor origin (Spiro et al 1993).…”

Section: Liver Involvementmentioning

confidence: 99%

“…The intrahepatic PTLD masses may become large tumors (Strouse et al 1996), sometimes reaching a diameter of 12 cm (Wu et al 2001). Burkitt lymphoma-like PTLD of the monomorphous type was observed in the grafted liver following OLT (Ulu et al 2007). In child with liver transplantation, liver nodules of PTLD underwent primary calcification (Lecouvet et al 1996).…”

Section: Liver Involvementmentioning

confidence: 99%

See 1 more Smart Citation

Posttransplant Lymphoproliferative Disorders (PTLDs)

Zimmermann

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in recipients of a solid organ, a bone marrow, or stem cell allografts. PTLDs include a broad spectrum of lesions that include early lesions (plasmacytic hyperplasia, infectious mononucleosis-like lesion), polymorphic PTLD, monomorphic PTLD (B-cell and T-cell variants), plasmacytoma-like lesions, and classical Hodgkin lymphomatype PTLD. PTLD usually presents between 6 and 17 months posttransplantation, in most cases with signs of systemic illness. Following liver transplantation, PTLD may develop in the liver, but overall this is a rare complication. The spectrum of hepatic PTLD after hepatic transplantation ranges from polymorphic PTLD to high-grade lymphomas and is most often related to EBV-infected lymphoid cells. Growth patterns comprise discrete nodules to diffuse patterns involving the entire organ.

show abstract

Section: Liver Involvementmentioning

confidence: 99%

Section: Liver Involvementmentioning

confidence: 99%

Posttransplant Lymphoproliferative Disorders (PTLDs)

Zimmermann

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

show abstract

Posttransplant Lymphoproliferative Disorders (PTLDs)

Zimmermann¹

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

Post-Transplant Lymphoproliferative Disorder

Oike

Egawa²,

Haga³

et al. 2015

Diagnostic Imaging: Gastrointestinal

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. Factors associated with increased risk of PTLD include mismatch of recipient and donor EBV serologic status (seronegative recipient with seropositive donor), and intensive drug-induced immunosuppression. Methods and results: We searched MEDLINE for articles published since 1970 to January 2009. Search terms included posttransplant lymphoproliferative disorder, immunosuppression, posttransplant malignancy, treatment, antiviral agents, rituximab, interferon alpha, chemotherapy, radiation, surgery. Studies in English of adult and pediatric populations after solid organ transplantation were selected and analyzed. Conclusion: Screening of patients at risk and balancing the intensity of immunosuppression against the risk of allograft rejection could reduce the risk of developing PTLD. In patients who develop PTLD, the severity and extent of disease should be examined and an individualized treatment plan including immunosuppression reduction and other agents should accordingly be chosen.

show abstract

Abdominal Computed Tomography Findings of Malignant Tumors in Patients With Solid Organ Transplants

Cited by 3 publications

References 13 publications

Posttransplant Lymphoproliferative Disorders (PTLDs)

Posttransplant Lymphoproliferative Disorders (PTLDs)

Posttransplant Lymphoproliferative Disorders (PTLDs)

Post-Transplant Lymphoproliferative Disorder

Contact Info

Product

Resources

About